Surgery Partners, Inc. (SGRY) Form 10-Q — Nov 9, 2026
Surgery Partners filed its Q3 2026 10-Q showing revenue of $815.3 million, down 0.8% year over year, with a net loss attributable to the company of $21.1 million ($0.16 per share). Days adjusted same-facility revenues grew 6.0%, driven by a 5.8% increase in revenue per case, but Adjusted EBITDA slipped 2.7% to $132.7 million. The dominant disclosure is the pending take-private merger: Spyglass Topco will acquire SGRY for $25.00 per share in cash under a merger agreement amended November 8, 2026, which added a 10% per annum ticking fee (max $1.61 per share) if closing slips past March 1, 2027. Upon closing, SGRY common stock will be delisted from Nasdaq.
Key figures
- Revenue
- 815.3
- Revenue Yoy
- -0.8%
- Cash Position
- 354.5
- Deal Value Usd
- approximately $796.6 million (Idaho Transaction consideration)
- Shares Outstanding
- 130881223
- Termination fee
- 149.1
- Ticking fee rate
- 10% per annum
- Revolver capacity
- 692.8
- Interest expense q3
- 67.9
- Merger outside date
- October 23, 2027
- Surgical facilities
- 173
- Term loan prepayment
- 285
- Merger per share price
- 25
- Adjusted ebitda q3 2025
- 136.4
- Adjusted ebitda q3 2026
- 132.7
- Operating cash flow ytd
- 174.5
- Adjusted ebitda ytd 2026
- 360.2
- Expense reimbursement cap
- 8.25
- Max ticking fee per share
- 1.61
- Same facility case growth q3
- 0.2%
- Same facility revenue growth q3
- 6.0%
- Same facility revenue per case growth q3
- 5.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.